Discovery and development of HIV-protease inhibitors

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

Retrieved on: 
Saturday, July 17, 2021
AIDS, Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Medical specialties, Hepatotoxins, Prevention of HIV/AIDS, HIV/AIDS, Management of HIV/AIDS, Zidovudine, HIV, Lenacapavir, Discovery and development of HIV-protease inhibitors, HIV vaccine development

If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.

Key Points: 
  • If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.
  • Lenacapavir is a potentially first-in-class capsid inhibitor without overlapping resistance with any currently approved antiretroviral therapy (ART).
  • Lenacapavir is a potential first-in-class, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection.
  • Data presented at AIDS 2020 from a Phase 1 study support further evaluation of lenacapavir administered subcutaneously every six months for both HIV-1 treatment and prevention.

Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections

Retrieved on: 
Monday, March 8, 2021
Protease inhibitor, HIV/AIDS, Antiviral drugs, Discovery and development of HIV-protease inhibitors, GC376

Ph.D., Executive Vice President, Head of Small Molecule Medicinal Chemistry and European Site Head at Aligos.

Key Points: 
  • Ph.D., Executive Vice President, Head of Small Molecule Medicinal Chemistry and European Site Head at Aligos.
  • We have also observed highly specific, selective activity in vitro that is consistent with the robust viral inhibition we see in aggressive animal models of infection.
  • These findings represent a significant advance toward a highly targeted therapeutic candidate that is urgently needed as the COVID-19 pandemic persists.
  • The demonstration of potent preclinical activity in Aligos viral protease inhibitor candidate is an important advancement toward this goal.

Technological Advances in the Anti-Viral Drug Therapy Market to Aid Treatment of COVID-19 Patients, Reports TBRC

Retrieved on: 
Thursday, May 14, 2020
Branches of biology, Biology, Enzymes, Reverse-transcriptase inhibitor, Protease inhibitor, Antiviral drug, Hepatotoxins, POL, Reverse transcriptase, Neuraminidase inhibitor, Resistance mutation, Discovery and development of HIV-protease inhibitors

Such initiatives and activities are projected to support the anti-viral drug therapy market growth to a significant extent.

Key Points: 
  • Such initiatives and activities are projected to support the anti-viral drug therapy market growth to a significant extent.
  • The use of certain existing anti-viral drugs for the covid-19 treatment is contributing to the growth of the anti-viral drugs market.
  • Increasing public-private funding for life science research globally is also expected to drive the growth of the global anti-viral drug therapy market.
  • Request A Free Sample Of The Anti-Viral Drug Therapy Market Report:
    The anti-viral drug therapy market is segmented by drug class into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.

KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

Retrieved on: 
Thursday, March 14, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Protease inhibitor, Medication, Kallikrein, Natural sciences, Life sciences, Health, Discovery and development of HIV-protease inhibitors, Aerie Pharmaceuticals

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal third quarter ended January 31, 2019.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal third quarter ended January 31, 2019.
  • Third Quarter and Recent Business Highlights:
    Provided a clinical update on oral plasma kallikrein inhibitors currently in the clinic.
  • KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.
  • Examples of forward-looking statements include, among others, available funding, our cash runway and future clinical trial timing and results.